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ABSTRACT
Objectives: The aim of the study was to measure advanced oxidation protein products (AOPPs) as markers for oxidative 
stress to evaluate cardiovascular risk in pre- and postmenopausal women and to compare the results with malondialde-
hyde (MDA) levels.
Material and methods: Twenty premenopausal women and 84 naturally postmenopausal patients were enrolled in the 
study. AOPP and MDA plasma levels were measured. The postmenopausal group was further subdivided into two groups: 
postmenopausal age of 40–49 and of 50–59 years. AOPP and MDA levels were compared between premenopausal, 40–49 and 
50–59 year old menopausal women.
Results: Plasma AOPP and MDA levels in postmenopausal women were increased when compared with their premeno-
pausal peers (123.83 ± 55.51 µmol/L vs. 61.59 ± 16.42 µmol/L and 6.50 ± 1.05 µmol/L vs. 5.98 ± 0.77 µmol/L; respectively). 
Mean plasma AOPP levels in the two menopausal age groups were both significantly higher from the premenopausal 
group (118.64 ± 59.1 µmol/L vs. 61.59 ± 16.42 µmol/L and 132.31 ± 48.97 µmol/L vs. 61.59 ± 16.42 µmol/L; respectively). 
No significant difference was found in mean AOPP levels between postmenopausal subjects of 40–49 and 50–59 years age 
(118.64 ± 59.12 µmol/L vs. 132.31 ± 48.97 µmol/L). Mean plasma MDA levels of each of two postmenopausal age groups were 
both significantly higher from the premenopausal group (6.50 ± 1.04 µmol/L vs. 5.98 ± 0.77 µmol/L and 6.50 ± 1.10 µmol/L 
vs. 5.98 ± 0.77 µmol/L; respectively). However, no statistically significant difference between the two postmenopausal age 
groups (6.50 ± 1.04 µmol/L vs. 6.50 ± 1.10 µmol/L) was found.
Conclusions: AOPP and MDA levels are elevated in postmenopausal women as compared to their premenopausal peers, 
suggesting they can be used as markers for cardiovascular risk in postmenopausal women.
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INTRODUCTION
Oxidative stress is defined as an imbalance between 
biochemical processes leading to the production of reactive 
oxygen species (ROS) and those responsible for the removal 
of ROS, the so-called ‘cellular antioxidant cascade’ [1]. Oxi-
dative stress is associated with damage to all biomolecules 
(polynucleotides, proteins, lipids, and sugars) that can lead 
to a critical failure of biological functions and, ultimately, 
cell death [2–4]. There is a growing evidence supporting the 
role of oxidative stress in the pathogenesis of certain chronic 
diseases (i.e. atherosclerosis, diabetes mellitus, chronic renal 
failure), certain cancers, and the process of aging [2, 5–9].
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Oxidative stress appears to play a key role in the de-
velopment of cardiovascular diseases related to athero-
sclerosis. Lipid peroxidation has long been shown to be 
associated with increased cardiovascular risk. The oxidative 
modification hypothesis of atherosclerosis suggests that 
low-density lipoprotein (LDL) oxidation is an important 
initiating event in atherogenesis [2, 5, 8]. Various products of 
free radical damage to biomolecules as well as antioxidant 
defense system mechanisms have been used as biomarkers 
of oxidative stress status in patients suffering from cardio-
vascular complications and other chronic diseases believed 
to be related to oxidative stress [10, 11]. Advanced oxida-
tion protein products (AOPPs) have been first described in 
the plasma of uremic patients at high levels as a marker 
of oxidant-mediated protein damage [12]. AOPPs are pre-
dominantly albumin and its aggregates, which are gener-
ated following exposure to reactive oxidants from activated 
phagocytes and have some pro-inflammatory properties 
[13, 14]. AOPPs are proposed as one of the possible mark-
ers of oxidative injury, which originate under oxidative and 
carbonyl stress and increase global inflammatory activity. 
Recently, elevated AOPP levels have also been reported to 
be associated with increased cardiovascular risk [15–17]. 
OBJECTIVES
Although increased blood levels of lipid peroxidation 
products (malondialdehyde levels) have been reported in 
postmenopausal women [18–20], there is only one study 
reporting AOPP levels in postmenopausal women [21].The 
aim of the study was to measure AOPP and MDA levels in 
pre and postmenopausal women.
MATERIAL AND METHODS
A total of 104 subjects were enrolled in the study, includ-
ing 40 premenopausal women (aged 40–49) with regular 
menses and 84 postmenopausal women (aged 40–59) with 
no menses for at least 1 year. Fifty-one of the menopausal 
women were between 40–49 and 33 were between 50– 
–59 years of age. All patients were healthy and had no history 
of vascular diseases related to atherosclerosis (i.e. coronary 
artery disease and hypertension) or any systemic diseases 
(i.e. chronic renal disease). Smokers, regular consumers of 
alcohol, antioxidant supplement users were also excluded 
from the study. None of the patients had taken any hormone 
replacement therapy or hormonal medication containing 
estrogen before the study. Local Ethics Committee approved 
of the study. All subjects provided their informed consent. 
Venous blood samples were drawn from patients in 
fasting state to heparin-coated, EDTA-containing tubes. Fol-
lowing centrifugation, the plasma was stored in Eppendorf 
tubes at –80°C until analysis. AOPP levels were determined in 
the plasma using a spectrophotometric method described 
by Witko-Sarsat et al. [12]. Next, 200 µL of plasma were di-
luted 1:5 with 0.1 mol/L, pH 7.4, phosphate-buffered saline 
solution (PBS) and 20 mL of acetic acid (14 mol/L) and 10 mL 
of 1.16 mol/L potassium iodide were added. Control wells 
contained PBS. Chloramine-T solution (0–100 μmol/L) was 
used for calibration. Absorbance was measured at 340 nm 
(Schimadzu UV1601) and AOPP concentration was ex-
pressed in chloramines-T units (μmol/L). MDA levels were 
determined in the plasma by means of the thiobarbituric 
acid (TBA) reaction, as described by Hammouda et al. [22]. 
A mixture of 0.5 mL of plasma, 2.5 mL of trichloroacetic acid 
(200 g/L), and 1 mL of TBA (6.7 g/L) was heated in a boiling 
water bath for 30 minutes then rapidly cooled. The red 
complex formed was extracted in 4 mL of n-butanol. Ab-
sorbance was measured at 532 nm (Schimadzu UV1601), 
and 1,1,3,3 tetraethoxypropane (Sigma-Aldrich) solution 
(0–20 μmol/L) was used for calibration. MDA concentration 
was expressed as μmol/L. 
The Statistical Program for Social Sciences (SPSS, ver-
sion 11.5; SPSS Inc., Chicago, IL) was used for statistical 
analysis. Plasma AOPP and MDA levels were expressed as 
mean ± standard deviation (x ± SD), and comparisons of 
these data were analyzed using student t-test or one-way 
ANOVA tests. Nonparametric ‘Two-sample Kolmogo-
rov-Smirnov’ and Kruskal-Wallis tests were used when as-
sumptions for the t-test and one-way Anova tests were not 
met. Relationships between parameters were determined 
by Pearson’s correlation coefficient. P< 0.05 was considered 
statistically significant. 
RESULTS 
Mean ages of premenopausal and postmenopausal 
women were 44.4 ± 3.27 (range: 40–49) and 48.8 ± 3.5 (range: 
40–59), respectively. AOPP levels of pre- and postmenopau-
sal women were found to be 61.59 ± 16.42 µmol/L and 
123.83 ± 55.51 µmol/L and MDA levels of pre- and post-
menopausal women were found to be 5.98 ± 0.77 µmol/L 
and 6.50 ± 1.05 µmol/L, respectively. Plasma AOPP and MDA 
levels in the postmenopausal women were increased when 
compared to their premenopausal peers (p < 0.05).
As the age range of the premenopausal group was 40– 
–49 years, the postmenopausal group was further subdivid-
ed into two groups as postmenopausal age of 40–49 years 
and postmenopausal age of 50–59 years to analyze the 
effect of age on AOPP and MDA levels. The results of the 
comparisons of mean plasma AOPP and MDA levels in the 
three groups are summarized in Table 1. Mean plasma AOPP 
levels of the two menopausal age groups were both signifi-
cantly higher than the premenopausal group (p < 0.001). 
When plasma AOPP levels were compared between the two 
postmenopausal groups, although mean plasma AOPP lev-
els of the older postmenopausal group were slightly higher 
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than the younger group, the difference was not statistically 
significant. Mean plasma MDA levels of the two postmeno-
pausal age groups were both significantly higher from the 
premenopausal group (p < 0.01). Mean plasma MDA levels 
were not statistically different between the two postmeno-
pausal age groups. 
When the association between plasma AOPP and MDA 
levels and age or duration of menopause was analyzed with 
bivariate correlation procedure, no association between 
MDA and AOPP levels and age or duration of menopause 
was found. Also, there was no correlation between AOPP 
and MDA levels (Table 2).
DISCUSSION 
Gender-specific differences in the incidence and sever-
ity of vascular diseases have been well-documented, with 
the lower incidence of cardiovascular diseases related to 
atherosclerosis in premenopausal women as compared to 
their postmenopausal peers or men of similar age [23]. The 
mechanisms responsible for these differences are likely to 
be multifactorial and ovarian sex-hormone dependent. The 
beneficial effect of ovarian sex-steroid production on the 
prevention of cardiovascular diseases has been confirmed 
by numerous reports linking oophorectomy, either before 
or after the menopause, to higher rates of cardiovascular 
diseases [24, 25]. Estrogen is the key hormone protect-
ing women from vascular diseases via physiological effects 
on the important endothelial events [26]. Estrogens also 
have favorable effects on vascular oxidative stress by either 
increasing bioavailability of the vasoprotective molecule 
endothelium-derived nitric oxide or by modulating the 
expression and function of enzymes producing ROS, as well 
as antioxidant enzymes [27]. An increase in vascular oxida-
tive stress in women after menopause has been reported in 
several studies [18–20, 28]. Furthermore, hormone replace-
ment therapy has been shown to improve oxidative stress 
status of postmenopausal women [18, 29–32].
Our study demonstrated the obvious differences of oxi-
dative stress markers between pre- and postmenopausal 
women. Although an increase in plasma levels of MDA, 
a marker of lipid peroxidation, in the postmenopausal period 
has been previously demonstrated [18–20], to the best of 
our knowledge this has been the first study to demon-
strate menopause-related increase in plasma AOPP levels 
— a novel marker of oxidative protein damage reported 
to be associated with increased cardiovascular risk. In our 
study, mean plasma AOPP levels were significantly higher in 
postmenopausal as compared to premenopausal women, 
suggesting that it can be used as a marker in studies inves-
tigating cardiovascular risk in postmenopausal period. In 
contrast to our findings, a recent study investigating the 
relationship between oxidative stress and menopausal sta-
tus found no differences in AOPP and MDA levels between 
pre- and postmenopausal women [21].
The value of AOPP assay as a marker for cardiovascular 
risk was reported in three other studies [15–17]. In two of 
these, the study populations were formed of non-uremic pa-
tients [15, 17]. Kaneda et al., reported higher AOPP levels in 
the plasma of the patients with coronary artery disease diag-
nosed by angiography as compared to subjects without cor-
onary artery disease [15]. They also found AOPP levels to be 
correlated with the severity of coronary artery disease. Skva- 
rilova et al., also reported an association between higher 
plasma AOPP levels and angiographically confirmed coro-
nary artery disease, and detected (ROC analysis) a cut-off 
level of 89 mmol/L to predict acute coronary syndrome with 
Table 1. Comparison of mean plasma AOPP and MDA levels between premenopausal, postmenopausal 40–49 and 50–59 years age women 
Premenopausal
Age 40–49
(n: 40)
(mean ± SD)
Postmenopausal
Age 40–49
(n: 51)
(mean ± SD)
Postmenopausal
Age 50–59
(n: 33)
(mean ± SD)
P level
Age (years) 44.4 ± 3.3 46.7 ± 2.1 52.3 ± 2.2 0.001
Duration of menopause (months) – 18.55 ± 7.42 21.58 ± 8.30 NS
AOPP [µmol/L] 61.59 ± 16.42* 118.64 ± 59.12* 132.31 ± 48.97* 0.001
MDA [µmol/L] 5.98 ± 0.77** 6.50 ± 1.04** 6.50 ± 1.10** 0.01
*One-way ANOVA test, premenopausal vs. postmenopausal 40–49 age groups, and premenopausal vs. postmenopausal 50–59 age groups (post-hoc Scheffe test, 
p = 0.001); **Kruskal-Wallis test, premenopausal vs. postmenopausal 40–49 age groups (Kolmogorov-Smirnov test, p = 0.01), and premenopausal vs. postmenopausal 
50–59 age groups (Kolmogorov-Smirnov test, p = 0.02). NS — not significant; AOPP — advanced oxidation protein products; MDA — malondialdehyde
Table 2. Correlations of AOPP, MDA, age and duration of menopause 
in study group
MDA
 
r
p
Age
 
r
p
Duration  
of menopause
r
p
AOPP 0.940.32
0.21
0.78
0.23
0.56
MDA 0.070.95
0.03
0.98
AOPP — advanced oxidation protein products; MDA — malondialdehyde
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64% sensitivity and 71% specificity [17]. Although study 
populations in these studies were older and their mean age 
was comparable to our study (around 60 years of age), it is 
not possible to compare AOPP levels from our study with 
other reports in the literature since only 25–36% of the 
cases were women. Further studies comparing AOPP levels 
between men and postmenopausal women of the same age 
groups, with or without coronary artery diseases, are needed 
to clarify the effect of age and gender on AOPP levels, as well 
as to detect critical cut-off levels to predict coronary artery 
disease in postmenopausal women [33]. 
Reports in the literature suggest that protein oxidation 
occurs in the plasma of coronary artery disease as well as 
uremic patients. AOPP levels were found to be significantly 
higher in the plasma of patients with coronary artery dis-
eases than those without coronary artery disease. Also, 
a significant correlation had been detected by ANOVA be-
tween AOPP quartiles and the score and severity of coronary 
artery disease using the Gensini scoring system [15]. AOPPs 
are significantly increased in patients with acute coronary 
syndromes with ST segment elevation, but also tend to 
increase in patients with non-ST elevation myocardial infarc-
tion [17]. AOPPs may be used as markers of oxidative stress 
and as a prognostic factor for severe forms of cardiovascular 
diseases.
In our study, MDA levels were also found to be higher 
in postmenopausal women as compared to their premeno-
pausal peers. Our results are consistent with the findings of 
a previous study comparing MDA levels between fertile and 
postmenopausal age groups [19]. Furthermore, two recent 
reports, investigating the effect of surgical menopause on 
oxidant and antioxidant status of perimenopausal patients, 
revealed that MDA levels were increased after surgical me- 
nopause [18, 20]. Theoretically, MDA levels might further 
increase as the menopause continues to progress. We could 
not find any association between MDA levels and duration 
of menopause. This is in contrast with a previous report de- 
monstrating a positive correlation between plasma MDA lev-
els and duration of menopause [34]. However, the relatively 
shorter, as compared to the previous report, mean duration 
of menopause in our study might obscure any such associa-
tion. Also, we were not able to find any association between 
AOPP levels and duration of menopause. 
Oxidative stress probably accompanies the process of 
aging. A variety of oxidative stress markers have been de- 
monstrated to change due to the aging process [9]. Al-
though oxidative vascular stress of young women has been 
known to be lower as compared to men [23], the combined 
effect of aging and menopause in older women as compared 
to men is less certain. Thus, comparison of oxidative stress 
markers between the two genders in the elderly is needed 
to evaluate the independent effect of menopause on oxi-
dative stress. MDA is one of the most often used biomark-
ers of oxidative stress on lipids associated with aging. An 
age-related increase in the plasma concentration of MDA 
has been documented in several studies [28, 33, 35, 36]. 
Miguel J et al., in their study on a group of healthy men and 
women ranging in age from 20 to 70 years, demonstrated 
an age-related increase in MDA levels only among the wom-
en [28]. In our study, no correlation between age and MDA 
levels was observed, possibly due to a narrow age range. 
In the elderly (aged between 61 and 70 years), mean serum 
MDA levels of women were interestingly higher than men in 
this study. Contrarily, although Özbay et al., demonstrated 
an age-related increase in MDA levels in healthy subjects 
aged between 9 to 71 years, they failed to demonstrate any 
gender differences in MDA levels in any age groups of 9–14, 
27–45, and 57–71 years [33]. 
Free oxygen radicals are mainly formed as the result of 
oxygen reduction which takes place in the mitochondria. 
Unless these radicals are not antagonized by anti-oxidative 
system, cellular damage occurs [37]. In recent years, re-
searchers have focused their attention on the role of these 
free radicals in the pathogenesis of many diseases, chief 
among them atherosclerosis, cancer, and diabetes. Ischemia, 
metabolic disorders, neutrophil activation, and cardiovascu-
lar diseases induce the production of free radicals and, con-
sequently, cell damage with endothelial dysfunction [38]. 
AOPPs are considered reliable markers to estimate 
the degree of oxidant-mediated protein damage. Also, 
they have been proposed as one of the possible markers 
of oxidative injury, which originates under oxidative and 
carbonyl stress and increases global inflammatory activ-
ity [17]. Recently, the importance of advanced AOPP in 
the pathogenesis of atherosclerosis has been pointed out. 
These products originate as the result of free radical action 
on proteins and may act as inflammatory mediators trigger-
ing the oxidative ‘ignition’ of neutrophils, monocytes and 
T-lymphocytes, thus leading to up regulation and excessive 
stimulation of dendritic cells. These processes may account 
for immune disorders in atherosclerosis [39]. On the other 
hand, the antagonistic effect of AOPPs on high-density 
lipoprotein receptor by blocking HDL receptor scavenger 
receptor class B type I (SR-BI) gives rise to inhibition of 
HDL, association to SR-BI and SR-BI-mediated cholesteryl 
ester uptake [40]. 
CONCLUSIONS
AOPP — as well as MDA — levels are elevated in post-
menopausal women as compared to their premenopausal 
peers, suggesting that they can be used as markers for 
cardiovascular risk in the postmenopausal period. As far as 
future research and preventative prospects are concerned, 
several important aspects need to be considered regarding 
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protein oxidation. Further studies will support the feasibility 
of assessing AOPP levels as predictive markers of cardiovas-
cular risk in postmenopausal women. 
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